Butterfield to Announce Second Quarter 2025 Financial Results on July 28, 2025 and Host Earnings Conference Call on July 29, 2025
Earnings conference call: Tuesday, July 29, 2025 at 10:00 a.m. Eastern Time
Dial-in information: +1 (844) 855 9501 (toll-free US) or +1 (412) 858 4603 (international)
Conference ID: Butterfield Group
Live audio webcast: A live audio webcast of the call can be accessed via Butterfield's investor relations page on Butterfield's website at https://www.butterfieldgroup.com/investor-relations/events-presentations
Replay: An audio replay of the call will be available at https://www.butterfieldgroup.com/investor-relations/events-presentations for 12 months beginning July 29, 2025.
About Butterfield:
Butterfield is a full-service bank and wealth manager headquartered in Hamilton, Bermuda, providing services to clients from Bermuda, the Cayman Islands, Guernsey and Jersey, where our principal banking operations are located, and The Bahamas, Switzerland, Singapore and the United Kingdom, where we offer specialized financial services. Banking services comprise deposit, cash management and lending solutions for individual, business and institutional clients. Wealth management services are composed of trust, private banking, asset management and custody. In Bermuda, the Cayman Islands and Guernsey, we offer both banking and wealth management. In The Bahamas, Singapore and Switzerland, we offer select wealth management services. In the UK, we offer residential property lending. In Jersey, we offer select banking and wealth management services. Butterfield is publicly traded on the New York Stock Exchange (symbol: NTB) and the Bermuda Stock Exchange (symbol: NTB.BH). Further details on the Butterfield Group can be obtained from our website at: www.butterfieldgroup.com.
BF-All
View source version on businesswire.com: https://www.businesswire.com/news/home/20250714994760/en/
Contacts
Investor Relations Contact: Noah FieldsInvestor RelationsThe Bank of N.T. Butterfield & Son LimitedPhone : (441) 299 3816E-mail : noah.fields@butterfieldgroup.com
Media Relations Contact: Nicky StevensGroup Strategic Marketing & CommunicationsThe Bank of N.T. Butterfield & Son LimitedPhone: (441) 299 1624E-mail: nicky.stevens@butterfieldgroup.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Asana to Announce Second Quarter Fiscal Year 2026 Financial Results on Wednesday, September 3, 2025
SAN FRANCISCO, August 01, 2025--(BUSINESS WIRE)--Asana, Inc. (NYSE: ASAN)(LTSE: ASAN), a leading work management platform for human + AI coordination, announced today that it will release financial results for the second quarter fiscal year 2026 on Wednesday, September 3, after the close of the U.S. markets. In conjunction with the announcement, the company will host a webcast on the same day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss the financial results. The live webcast and replay will be available on the Asana Investor Relations website at About Asana Asana is a leading work management platform for human + AI coordination. Over 170,000 customers like Accenture, Amazon, Anthropic, Morningstar, and Suzuki rely on Asana to align teams and accelerate organizational impact. Whether it's managing strategic initiatives, cross-functional programs, or company-wide goals, Asana helps organizations bring clarity to complexity—turning plans into action with AI working alongside teams every step of the way. To learn more, visit View source version on Contacts Eva LeungAsana Investor RelationsIR@ Frances WardAsana CommunicationsPress@ Sign in to access your portfolio
Yahoo
a minute ago
- Yahoo
First Solar Stock Jumps After Q2 Beat and Raised Full-Year Outlook
Aug 1 - First Solar (NASDAQ:FSLR) gained 6.5% on Friday afternoon after posting second?quarter results that topped Wall Street expectations and prompted the solar manufacturer to raise its full?year guidance. Warning! GuruFocus has detected 5 Warning Signs with FSLR. The company reported Q2 net income of $341.9 million, or $3.18 per share, compared with $349.4 million, or $3.25 per share, a year ago. Analysts surveyed by FactSet expected $2.66 per share. Revenue climbed to $1.1 billion from $1.01 billion a year earlier, driven by higher sales of solar modules to third?party customers. Management now projects 2025 revenue between $4.9 billion and $5.7 billion, up from a prior $4.5 billion to $5.5 billion. Earnings guidance tightened to $13.50$16.50 per share, versus the earlier $12.50$17.50 range. First Solar also raised the lower end of its full?year solar module shipment target to 16.719.3 GW and adjusted its gross margin outlook to $2.05$2.35 billion. CEO Mark Widmar said the company benefits from President Trump's recently enacted tax law, which favors U.S.?made solar panels while limiting credits tied to Chinese supply chains. Analysts note that ongoing trade and tariff uncertainty still poses challenges but may also create opportunities for domestic manufacturers. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
Why Novo Nordisk Stock Imploded This Week
Key Points Novo Nordisk shares dropped after slashing full-year sales guidance, primarily due to weakening sales of its blockbuster GLP-1 drugs, Ozempic and Wegovy. Competition from "compounders" marketing tailored versions of GLP-1 treatments is putting pressure on drug sales. Despite short-term challenges, Novo stock trades at one of its lowest P/E ratios in the last 30 years. 10 stocks we like better than Novo Nordisk › Shares of Novo Nordisk (NYSE: NVO) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P 500 lost 2.4%, and the Nasdaq-100 lost 2.2%. The Danish pharmaceutical giant's stock was hit after it released disappointing earnings showing that sales of its blockbuster GLP-1 drugs remain weaker than hoped. Novo Nordisk disappoints Novo Nordisk was forced to cut guidance for its top-line sales, driven primarily by lagging sales of its GLP-1 drugs, Ozempic and Wegovy. The company says it now expects full-year sales growth of 8% to 14%, down significantly from its earlier range of 13% to 21%. Its guidance for operating profit was cut as well, from between 16% and 24% to between 10% and 16%. Wegovy and Ozempic have been absolute blockbusters for the company, propelling Novo to the most valuable company in Europe before competition from "compounders" -- companies that market their own tailor-made versions using its active ingredients -- impacted sales. Is this a buying opportunity? I think Novo does have significant issues it must overcome, but I think these fears are overblown. For long-term investors, this seems like a great time to buy in. The company's stock is trading at one of its lowest price-to-earnings ratios (P/E) in nearly 30 years and the lowest in at least five years. This seems like an opportunity to me. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Johnny Rice has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Novo Nordisk Stock Imploded This Week was originally published by The Motley Fool
